Back to News
Market Impact: 0.25
Grünenthal presents Phase III results for Qutenza® in post-surgical neuropathic pain at IASP 2026 World Congress on Pain
Source: PR Newswire
Healthcare & Biotech
Late-breaking Phase III RISE trial data were reported to further strengthen the established efficacy and safety profile of Qutenza®. The excerpt describes post-surgical neuropathic pain as affecting millions of patients annually but provides no trial results, numerical data, or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Artiva halts AlloNK development, cuts 94% of workforce
- Universal Health Services falls 3% on legal settlement concerns
- Midterm elections: How affordability and the economy could impact voters
- Why is Artiva Biotherapeutics stock collapsing today?
- adar1 capital management buys $53,691 of NextCure stock
- Zura Bio shares jump on Wedbush buy call ahead of trial data